United States:
Novel Pyrrolo[3,2-D]Pyrimidine Compounds Target Mitochondrial And Cytosolic One-Carbon Metabolism With Broad-Spectrum Antitumor Efficacy
26 July 2019
Kramer Levin Naftalis & Frankel LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Intellectual Property scientific advisor Khushbu Shah
co-authored an article titled “Novel Pyrrolo[3,2-d]Pyrimidine
Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism
with Broad-Spectrum Antitumor Efficacy” which was published
in AACR Journals on July 9, 2019. The article describes
structure-activity relationships and identifies exciting new drug
prototypes for development as multi-targeted antitumor agents.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...
